Endocrinol Metab.  2024 Dec;39(6):850-852. 10.3803/EnM.2024.2098.

Reframing the Paradigm: A Nuanced Approach to Prolactinoma Management

• Kim JH

• KMID: 2562712
• DOI: http://doi.org/10.3803/EnM.2024.2098

Figure

• 

  Fig. 1. Reframing the treatment algorithm for prolactinoma. HRT, hormone replacement therapy; PRL, prolactin; MRI, magnetic resonance imaging.

Reference

1. Chanson P, Maiter D. The epidemiology, diagnosis and treatment of prolactinomas: the old and the new. Best Pract Res Clin Endocrinol Metab. 2019; 33:101290.

2. Park JS, Yun SJ, Lee JK, Park SY, Chin SO. Descriptive epidemiology and survival analysis of prolactinomas and Cushing’s disease in Korea. Endocrinol Metab (Seoul). 2021; 36:688–96.

3. Petersenn S, Fleseriu M, Casanueva FF, Giustina A, Biermasz N, Biller BM, et al. Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society International Consensus Statement. Nat Rev Endocrinol. 2023; 19:722–40.

4. Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA, et al. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011; 96:273–88.

5. Wang XB, Han TY, Ma JG, He C, Xue L, Zhang X, et al. Pseudocapsule and pseudocapsule-based extracapsular resection in pituitary neuroendocrine tumors. Front Endocrinol (Lausanne). 2022; 13:1056327.

6. Zamanipoor Najafabadi AH, Zandbergen IM, de Vries F, Broersen LH, van den Akker-van Marle ME, Pereira AM, et al. Surgery as a viable alternative first-line treatment for Prolactinoma patients: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2020; 105:e32–41.

7. Dekkers OM, Lagro J, Burman P, Jorgensen JO, Romijn JA, Pereira AM. Recurrence of hyperprolactinemia after withdrawal of dopamine agonists: systematic review and meta-analysis. J Clin Endocrinol Metab. 2010; 95:43–51.

8. Steeds R, Stiles C, Sharma V, Chambers J, Lloyd G, Drake W. Echocardiography and monitoring patients receiving dopamine agonist therapy for hyperprolactinaemia: a joint position statement of the British Society of Echocardiography, the British Heart Valve Society and the Society for Endocrinology. Clin Endocrinol (Oxf). 2019; 90:662–9.

9. Wright K, Chaker L, Pacione D, Sam K, Feelders R, Xia Y, et al. Determinants of surgical remission in prolactinomas: a systematic review and meta-analysis. World Neurosurg. 2021; 154:e349–69.

10. Menucci M, Quinones-Hinojosa A, Burger P, Salvatori R. Effect of dopaminergic drug treatment on surgical findings in prolactinomas. Pituitary. 2011; 14:68–74.

11. Zandbergen IM, Zamanipoor Najafabadi AH, Pelsma IC, van den Akker-van Marle ME, Bisschop PH, Boogaarts HD, et al. The PRolaCT studies: a study protocol for a combined randomised clinical trial and observational cohort study design in prolactinoma. Trials. 2021; 22:653.

12. Hage C, Salvatori R. Predictors of the response to dopaminergic therapy in patients with prolactinoma. J Clin Endocrinol Metab. 2020; 105:dgaa652.

13. Ji MJ, Kim JH, Lee JH, Lee JH, Kim YH, Paek SH, et al. Best candidates for dopamine agonist withdrawal in patients with prolactinomas. Pituitary. 2017; 20:578–84.

14. Kim K, Park YW, Kim D, Ahn SS, Moon JH, Kim EH, et al. Biochemical remission after cabergoline withdrawal in hyperprolactinemic patients with visible remnant pituitary adenoma. J Clin Endocrinol Metab. 2021; 106:e615–24.

15. Kim D, Ku CR, Kim K, Jung H, Lee EJ. Prolactin ≤1 ng/mL predicts macroprolactinoma reduction after cabergoline therapy. Eur J Endocrinol. 2020; 182:177–83.